272 related articles for article (PubMed ID: 34729526)
1. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
[TBL] [Abstract][Full Text] [Related]
3. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Campbell CM; LoRusso S; Dispenzieri A; Kristen AV; Maurer MS; Rapezzi C; Lairez O; Drachman B; Garcia-Pavia P; Grogan M; Chapman D; Amass L;
Cardiol Ther; 2022 Sep; 11(3):393-405. PubMed ID: 35583798
[TBL] [Abstract][Full Text] [Related]
4. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
7. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Kristen A; Wixner J; Diemberger I; Gonzalez-Moreno J; Cariou E; Maurer MS; Planté-Bordeneuve V; Garcia-Pavia P; Tournev I; Gonzalez-Costello J; Duarte AG; Grogan M; Mazzeo A; Chapman D; Gupta P; Glass O; Amass L;
Orphanet J Rare Dis; 2023 Nov; 18(1):350. PubMed ID: 37946256
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
Dispenzieri A; Coelho T; Conceição I; Waddington-Cruz M; Wixner J; Kristen AV; Rapezzi C; Planté-Bordeneuve V; Gonzalez-Moreno J; Maurer MS; Grogan M; Chapman D; Amass L;
Orphanet J Rare Dis; 2022 Jun; 17(1):236. PubMed ID: 35717381
[TBL] [Abstract][Full Text] [Related]
9. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
10. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
11. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS.
Gentile L; Tournev I; Amass L; Chapman D; Mazzeo A;
Cardiol Ther; 2021 Dec; 10(2):481-490. PubMed ID: 34148211
[TBL] [Abstract][Full Text] [Related]
13. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Waddington-Cruz M; Wixner J; Amass L; Kiszko J; Chapman D; Ando Y;
Neurol Ther; 2021 Dec; 10(2):753-766. PubMed ID: 34024024
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Damy T; Kristen AV; Suhr OB; Maurer MS; Planté-Bordeneuve V; Yu CR; Ong ML; Coelho T; Rapezzi C;
Eur Heart J; 2022 Feb; 43(5):391-400. PubMed ID: 30938420
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Dispenzieri A; Grogan M; Coelho T; Tournev I; Waddington-Cruz M; Wixner J; Diemberger I; Garcia-Pavia P; Chapman D; Gupta P; Glass O; Amass L;
Cardiol Ther; 2024 Mar; 13(1):117-135. PubMed ID: 38117424
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.
Živković SA; Lacomis D; Soman P
Front Cardiovasc Med; 2024; 11():1345608. PubMed ID: 38410247
[TBL] [Abstract][Full Text] [Related]
19. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
20. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
